Safety Data Sheet



1. IDENTIFICATION				
Product Information				
Product name	ELIQUIS® (apixaban)Tablets, 2.5 mg & 5	5.0 mg		
Version	1.1, 07.03.2013			
Jurisdiction	This Safety Data Sheet was prepared in accordance with the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) for the United States of America (USA) (CFR 1910.1200), European Union (EU) (EC 1272/2008) and United Nations (UN). The following countries utilize the UN GHS classification process: Mexico, Brazil, China, New Zealand, Canada, Japan, Korea and Australia.			
Active substance	Apixaban			
Synonyms	BMS-562247-01 Tablets; BMS 562247-01 Tablets; AG0023 Tablets; DPH-150123 Tablets			
Other information	Project Name: 020F6			
Intended Uses	This material is a finished drug product for patient use. The primary indication is thrombosis.			
Company/Undertaking Ia	lentification			
Address	<u>USA</u> Bristol-Myers Squibb Company P.O. Box 191 New Brunswick, New Jersey 08903 United States of America	Ireland Bristol-Myers Squibb Company Swords Laboratories, Watery Lane Swords, Ireland MG-GBS-MSDS-Request@bms.com		
Emergency Phone Number	USA (also Canada, Puerto Rico and the Virgin Island): 1-800-424-9300			
	Other Countries: See "Section 16" for council CHEMTREC.	ntry-specific emergency phone numbers from		

2. HAZARDS IDENTIF	2. HAZARDS IDENTIFICATION			
Classification and L	abelling Common to All Jurisdictions			
Classification	Serious Eye Damage/Eye Irritation - Category 2 Carcinogenicity - Category 2 Specific Target Organ Systemic Toxicity (Single Exposure) - Category 3			
Symbol				
Hazard Statements	Causes serious eye irritation. Suspected of causing cancer. (inhalation). May cause respiratory irritation .			
Precautionary Statements	Do not breathe dust/fume/gas/mist/vapours/spray. Wash thoroughly after handling. Wear protective gloves/clothing and eye/face protection. Use personal protective equipment as required.			

2. HAZARDS IDENTIF	ICATION
	Use only outdoors or in a well-ventilated area. Obtain special instructions before use.
Classification and I	abelling for Specific Jurisdictions
USA	
Classification	Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1
Signal Word	Danger
Hazard Statements	Causes damage to organs (blood, central nervous system, cardiovascular system, eyes) through prolonged or repeated exposure.
Precautionary Statements	Do not eat, drink or smoke when using this product.
EU	
Classification	Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 2
Signal Word	Warning
Hazard Statements	May cause damage to organs (blood, central nervous system, cardiovascular system, eyes) through prolonged or repeated exposure.
UN	
Classification	Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1
Signal Word	Danger
Hazard Statements	Causes damage to organs (blood, central nervous system, cardiovascular system, eyes) through prolonged or repeated exposure.
Precautionary Statements	Do not eat, drink or smoke when using this product.

3. COMPOSITION/INFORMATION ON INGREDIENTS					
			EU only		
Components	Concentration	CAS-No.	EINECS/ELINCS/ REACH Registration Number	Symbol(s)/ R-phrase(s)	H-code(s)
Hazardous components Apixaban	2.4 %	Trade Secret		T: R48/25	H372
Microcrystalline Cellulose	< 40 %	9004-34-6	232-674-9	Xi: R37	H335

Sodium Lauryl Sulfate	< 1 %	151-21-3	205-788-1	Xn, Xi, N:	H302
, j				R21, R22,	H311
				R36/37/38,	H315
				R51/53	H318
					H335
Magnesium Stearate	< 5 %	557-04-0	209-150-3		H372
Hydroxypropyl Methylcellulose	< 5 %	9004-65-3			H372
Titanium Dioxide	< 1 %	13463-67-7	236-675-5	Xi, Xn:	H351
				R37, R40,	H335
				R53	H372
					H413
Other ingredients					
Non-Hazardous Ingredients	< 50 %	Not available			
See section 16 for Symbol, R-	phrase and H-c	ode text.			

4. FIRST AID MEASURES	
Eye contact	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical advice/attention.
Skin contact	Take off contaminated clothing and shoes immediately. Wash off immediately with plenty of water for at least 15 minutes. If exposed or concerned: Get medical attention/advice.
Inhalation	IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/physician if you feel unwell.
Ingestion	Do NOT induce vomiting. Never give anything by mouth to an unconscious person. If exposed or concerned: Get medical attention/advice.
Notes to Physician	This product has been reported to interact with the following medications: drugs that inhibit cytochrome P-450. Refer to Section 11.
Medical Surveillance	A pre-placement physical examination and history for employees with potential exposure to this compound is recommended. Baseline testing would include: a medical history with emphasis on unusual bleeding, a complete blood count with differential. Based on opportunity for exposure and duration of exposure a periodic follow-up examination may be considered. This exam should be overseen by a physician thoroughly knowledgeable about both the toxicity of this compound and the extent of work place exposure. It is recommended that the content be similar to the pre-placement exam. Employees who are pregnant, are breast-feeding, or who are concerned with other reproductive issues should be encouraged to consult with the occupational health physician monitoring worker's health.

5. FIRE-FIGHTING MEASURES		
Flammable Properties	Not available	
Extinguishing Media	Suitable extinguishing media: Dry chemical, Water spray, Foam Unsuitable extinguishing media: Do NOT use water jet.	

Page 4 of 18

5. FIRE-FIGHTING MEASURES			
Protection of Firefighters	 Specific hazards: Eye irritant Respiratory Irritant Protective equipment: Use personal protective equipment. In the event of fire, wear self-contained breathing apparatus. Hazardous Combustion Products: carbon oxides (COx), nitrogen oxides (NOx), and, sulphur compounds 		
Other information	Decontaminate protective clothing and equipment before reuse.		

6. ACCIDENTAL RELEAS	6. ACCIDENTAL RELEASE MEASURES			
Personal precautions	Refer to protective measures listed in sections 7 and 8. Use personal protective equipment. Examples include tightly fitting safety goggles, lab coat and impervious gloves. Wear respiratory protection. Depending on the nature of the spill (quantity and extent of spill) additional protective clothing and equipment such as a self-contained breathing apparatus may be needed.			
Environmental precautions	Prevent release to drains and waterways. Prevent release to the environment.			
Containment Methods	Wet down any dust to prevent generation of aerosols, if appropriate. Cover with suitable material.			
Cleanup Methods	Contain and collect spillage and place in container for disposal according to local regulations (see Section 13). Handle waste materials, including gloves, protective clothing, contaminated spill cleanup material, etc., as appropriate for chemically and pharmacologically similar materials.			

7. HANDLING AND STORAGE				
Handling Precautions	Avoid exposure - obtain special instructions before use. Avoid formation of dust and aerosols. When handling broken or crushed tablets or capsules, ensure worker exposure is below the recommended exposure limit. Keep away from heat and sources of ignition. Prevent release to drains and waterways. Use only outdoors or in a well-ventilated area.			
Container Requirements	Store in the original primary packaging as provided. Keep container tightly closed.			
Storage Conditions	Store at 15-25 °C. Protect against light. Keep away from heat, sparks and flames. Store in well-ventilated place.			
Specific use(s)	Refer to Section 1			

8. EXPOSURE CONTROLS / PERSONAL PROTECTION					
Exposure limit(s)	Company Guideline	ACGIH	Germany OEL	UK MEL	
Apixaban	3 μg/m3 8 hour-TWA				
Microcrystalline Cellulose		10 mg/m3 TWA			
Magnesium Stearate		10 mg/m3 TWA			
Titanium Dioxide		10 mg/m3 TWA			

8. EXPOSURE CONTR	OLS / PERSONAL PROTECTION	1		
Red Iron Oxide		5 mg/m3 TWA dust and fume, as Fe 1 mg/m3 TWA as Fe	6 mg/m3 TWA respirable fraction 1.5 mg/m3 MAK respirable fraction	10 mg/m3 STEL fume, as Fe 2 mg/m3 STEL as Fe 5 mg/m3 TWA fume, as Fe 1 mg/m3 TWA as Fe
Microcrystalline Cellulose	Occupational Exposure Limi - Belgium - Switzerland - E		2	al
Magnesium Stearate	Occupational Exposure Limi - Belgium - Spain - Ireland			
Titanium Dioxide	Occupational Exposure Limits have been established by: - Austria - Belgium - Switzerland - Denmark - Estonia - Spain - France - Greece - Ireland - Norway - Poland - Portugal - Sweden			
Red Iron Oxide	Occupational Exposure Limi - Austria - Belgium - Switz - France - Greece - Hungary Sweden	erland - Czech Repu	blic - Denmark - Este	
Recommended Industrial Hygiene Monitoring Methods	Contact the Bristol-Myers Squibb AIHA accredited Industrial Hygiene Laboratory at 732-227-6338. See Section 4 "Notes to Physician" for information on medical surveillance.			
EXPOSURE CONTRO	OLS / PERSONAL PROTECTIO	ON FOR MATERIAL	AS SUPPLIED	
	ELIQUIS® (apixaban)Tablet 2 Material is assigned to E		d 2 (range 100 - 1000	ug/m3).
Engineering Controls and Ventilation	FOR MANUFACTURING I technology, or other enginee exposure limit. When handling general laboratory dilution va- handling quantities from 150 fume hood; biological safety local exhaust. Quantities exe A laminar flow/powder conta active substance. For manuf transfer systems and contain exhaust is required. FOR CLINICAL SETTING clinical setting, good room v be needed.	ring controls to keep ing quantities up to 1 entilation (e.g. 6-12 a milligrams to 1 kilo cabinet(Class II, all ceeding 1 kilogram si tainment booth is rec acturing and pilot pla ment of open operation USE (DRUG PROD	airborne levels below 50 milligrams, a standa air changes per hour) is gram, work in a standa types), approved vento hould be handled in a c ommended for handlin ant operations, use sem ons. HEPA filtration f	recommended ard laboratory with a appropriate. When and laboratory using a ed enclosure; specific designated laboratory. g >1 kilograms of i to closed material for recirculation of g small quantities in a

8. EXPOSURE CONTROLS / PERSONAL PROTECTION		
Respiratory protection	Use and selection of respiratory protection is based upon engineering controls in use and potential for aerosol generation. When engineering controls are not sufficient control exposure, wear an approved respirator with NIOSH Class 100 or high efficiency particulate (HEPA) filters or cartridges (EN 140/EN 136) when exposures are up to 10 times the exposure control guideline. Wear a loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator (PAPR) (EN 12941) when exposures are 10-25 times the exposure control guideline. Wear a full facepiece negative pressure respirator with Class 100 or HEPA filters (EN 136) when exposures are 25-50 times the exposure control guideline. Wear a tight-fitting, full facepiece HEPA PAPR (EN 12942) when exposures are 50-100 times the exposure control guideline. Wear a hood-shroud HEPA PAPR (EN 12941) or full facepiece supplied air respirator (EN 139) operated in a pressure demand or other positive pressure mode when exposures are 100-1000 times the exposure control guideline.	
Eye protection	Safety glasses with side-shields are recommended (EN 166). Face shields or chemical safety goggles (EN 166) may be required if splash potential exists or if corrosive materials are present. Note: Choice of eye protection may be influenced by the type of respirator which is selected.	
Hand protection	Impervious nitrile, rubber and latex gloves are recommended (EN 420, EN 374). If material is handled in solution, the solvent should also be considered when selecting protective clothing material. Please note that employees who are allergic to natural rubber latex should use nitrile gloves.	
Skin and body protection	FOR MANUFACTURING PROCESSES (BULK): Wear a laboratory coat (EN 340) when handling quantities up to 1 kilograms. For quantities over 1 kilogram, wear laboratory coat (EN 340) or coverall of low permeability (EN 1149-1). For manufacturing operations, wear coverall of low permeability (EN 1149-1). FOR CLINICAL SETTING USE (DRUG PRODUCT): When handling small quantities in a clinical setting, good room ventilation is desirable. Specific engineering controls should not be needed.	
Hygiene	Wash hands and face before breaks and immediately after handling the product.	
Environmental exposure controls	Prevent release to drains and waterways.	

9. PHYSICAL AND CHEMICAL PROPERTIES		
General Information		
Appearance		
Physical State	solid	
Color	yellow pink brown or white to off-white	
Form	tablet	
Odour		
Odour	Not available	
Odor Threshold	Not available	
рН	Not available	
Other information		
Bulk density	Not available	
Evaporation rate	Not available	
Molecular formula	Not applicable	
Hydrolysis/Photolysis	Not available	

PHYSICAL AND CHEMICAL PROPERTIES		
Hygroscopicity	Not available	
Molecular Weight	Not applicable	
Log Octanol/Water Partition Coeff [log Kow]	Not available	
Surface Tension	Not available	
рКа	Not available	
Particle Size	Not available	
Solubility, Water	Not available	
Specific Gravity/ Relative density	Not available	
Viscosity, dynamic	Not available	
Viscosity, kinematic	Not available	
% Volatile	Not available	
Thermal/Stability properties		
Autoignition temperature	Not available	
Boiling Point	Not available	
Thermal decomposition	Not available	
Explosive Limits, LEL	Not available	
Explosive limits, UEL	Not available	
Explosiveness	Not available	
Flammability	Not available	
Flash point	Not available	
Melting Point	Not available	
Oxidizing Potential	Not available	
Vapor Properties		
Vapor Density	Not available	
Vapor Pressure	Not available	
Saturated Vapor Concentration	Not available	

10. STABILITY AND REACTIVITY		
Stability		
Chemical Stability	Stable under normal conditions.	
Conditions to avoid	Not available	
Materials to avoid	Not available	
Hazardous decomposition products	Hazardous decomposition products formed under fire conditions.: carbon oxides (COx), nitrogen oxides (NOx), and, sulphur compounds	
Hazardous reactions	None known.	
Sensitivity to static di	scharge/Dust exp.	
Summary Statements	Although material has not been specifically tested, fine dust suspended in air in sufficient concentration and in the presence of an ignition source may pose a potential explosion hazard. Provide appropriate bonding and grounding protection to control static charge. Powder handling equipment such as dust collectors, dryers, and mills may require additional protective measures (e.g. explosion venting, inerting, etc.).	

11. TOXICOLOGICA	11. TOXICOLOGICAL INFORMATION		
Routes of Entry	Ingestion, inhalation, Eye contact, Skin contact		
Eye Irritation	<u>Apixaban</u> Not an eye irritant based on in vitro assay		
	Microcrystalline Cellulose Mildly irritating to eyes.		
	Sodium Lauryl Sulfate Severely irritating to eyes.		
	Magnesium Stearate May cause mechanical irritation.		
	<u>Hydroxypropyl Methylcellulose</u> Dust may cause mechanical irritation.		
	<u>Titanium Dioxide</u> Dust may cause mechanical irritation.		
Skin Irritation	<u>Apixaban</u> Not irritating to skin.		
	Microcrystalline Cellulose Not irritating to skin.		
	Sodium Lauryl Sulfate Irritating to skin.		
	Magnesium Stearate May cause mechanical irritation.		
	<u>Titanium Dioxide</u> Dust may cause mechanical irritation.		
Respiratory Irritation	Microcrystalline Cellulose Respiratory Irritant		
	Sodium Lauryl Sulfate Irritating to respiratory tract.		
	<u>Titanium Dioxide</u> Irritating to respiratory tract.		

11. TOXICOLOGICAL INFORMATION

Sensitization	<u>Apixaban</u> Not a dermal sensitizer in an experimental study
	Microcrystalline Cellulose Not a dermal sensitizer
	Sodium Lauryl Sulfate Allergic contact dermatitis is quite rare but has been reported.
	<u>Titanium Dioxide</u> Not a dermal sensitizer

Page 10 of 18

Acute Toxicity	Acute Oral
Study	Apixaban
Judy	LD50 (rat, males and females): $> 4,510 \text{ mg/kg}$
	LD50 (muse, males and females): > 4,000 mg/kg
	Minimum lethal dose (monkey, males and females): 100 mg/kg Hemorrhaging was
	considered secondary to inadvertent arterial puncture in association with drug treatmen
	LD50 (dog, females): > 1,500 mg/kg No mortality occurred.
	<u>Microcrystalline Cellulose</u> LD50 (rat, males and females): > 5,000 mg/kg
	Sodium Lauryl Sulfate
	LD50 (rat): 1,288 mg/kg
	<u>Titanium Dioxide</u>
	LD50 (rat): > 10,000 mg/kg
	LD50 (rat): >10,000 mg/kg
	Acute Dermal
	Microcrystalline Cellulose
	LD50 (rat, males and females): $> 2,000 \text{ mg/kg}$
	Sodium Lauryl Sulfate
	LD50 (rat): > 2,000 mg/kg
	LD50 (rabbit): 580 mg/kg
	LD50 (rabbit): 580 mg/kg
	LD50 (rabbit): 580 mg/kg
	LD50 (rabbit): 580 mg/kg
	LD50 (guinea pig): 1,200 - 2,000 mg/kg
	<u>Titanium Dioxide</u>
	LD50 (rabbit): >10,000 mg/kg
	LD50 (rabbit): >10,000 mg/kg
	Acute inhalation toxicity
	Microcrystalline Cellulose
	LC50 (rat, males and females): $> 5350 \text{ mg/m3/4 H}$
	Sodium Lauryl Sulfate
	LC50 (rat): $> 3,900 \text{ mg/m3/1hr/1 H}$
	<u>Titanium Dioxide</u>
	LC50 (rat): $> 2.29 \text{ mg/l/4 H/4 H}$
	Acute toxicity (other routes of administration)
	Apixaban
	LD50 (mouse, males and females, intravenous): 50 mg/kg
	Microcrystalline Cellulose
	LD50 (rat, males, intraperitoneal): $> 3,160 \text{ mg/kg}$
	<u>Hydroxypropyl Methylcellulose</u>
	LD50 (rat, intraperitoneal): 5,200 mg/kg
	LD50 (mouse, intraperitoneal): 5,000 mg/kg

11. TOXICOLOGICAL INFORMATION		
Repeated Dose Toxicity	 <u>Apixaban</u> 12 weeks - 105 weeks oral (daily) mouse, rat, dog study (males and females): NOAEL = 5 mg/kg; Low dose effects include: minimal changes in clinical chemistry parameters, changes in blood clotting parameters. High dose microscopic effects include: lymph nodes. After recovery, all parameters returned to normal. 2 Weeks intravenous (daily) dog study (males and females): NOAEL = 0.4 mg/kg; Low dose effects include: minimal changes in clinical pathology parameters, changes in blood clotting parameters. 	
	Sodium Lauryl Sulfate 2 Years Dietary (daily) rat study : NOAEL = 1%; No significant adverse effects were observed.	
	Magnesium Stearate 3 months Dietaryrat study : NOAEL = 2,500 mg/kg; Low dose effects include: decreased weight gain, liver effects, kidney stones.	
	<u>Titanium Dioxide</u> Assessment Repeat Dose Toxicity Several studies were conducted. See "Human Experience".	
Genetic Toxicity	Apixaban In vitro Ames reverse-mutation assay negative Chromosome aberration test in vitro negative in vivo 3 Days oral, Mutagenicity (micronucleus test) (rat) negative 1 months oral, Chromosomal aberrations (rat) negative Mutagenicity Assessment This material was negative in a battery of in vivo and in vitro genotoxicity assays. Microcrystalline Cellulose Mutagenicity Assessment This material was negative in a battery of in vivo and in vitro genotoxicity assays. Sodium Lauryl Sulfate Mutagenicity Assessment	
	Several studies were conducted. This material was negative in a battery of in vivo and in vitro genotoxicity assays. Not considered a mutagen according to 29 CFR 1910, 67/348/EC or Canadian Controlled Products Regulations. <u>Titanium Dioxide</u> Mutagenicity Assessment This material was negative in a battery of in vivo and in vitro genotoxicity assays.	

Carcinogenicity	Anivahan		
Carcinogenicity	Apixaban 104 Weeks Dietary (daily) rat study : Tumor NOAEL = 600 mg/kg (males and females). No treatment-related tumors were observed. 104 Weeks Dietary (daily) mouse study : Tumor NOAEL = 1,500 mg/kg (males and females). No treatment-related tumors were observed. Carcinogenicity Assessment This material did not show carcinogenic potential in animal studies. Microcrystalline Cellulose Carcinogenicity Assessment This material did not show carcinogenic potential in animal studies. Not classifiable as to its carcinogenicity to humans. Magnesium Stearate Carcinogenicity Assessment Not classifiable as to its carcinogenicity to humans. Titanium Dioxide Carcinogenicity Assessment Tumors were observed at high dose in animal studies by inhalation and intratracheal administration. Tumors were not observed by other routes.		
Carcinogenicity	ACGIH	IARC	NTP
Apixaban			
Microcrystalline Cellulose			
Sodium Lauryl Sulfate			
Magnesium Stearate	A4		
Hydroxypropyl Methylcellulose			
Titanium Dioxide	A4	2B	
Reproductive Toxicity	 <u>Apixaban</u> 2 Weeks oral (daily) exposure time = 45 Days Study of Fertility and Early Embryonic Development (rat) (males and females) LOAEL = 50 mg/kg Effects include: changes in blood clotting parameters. No effects were found on matin or fertility. Assessment Reproductive Toxicity Data indicate that this compound is not a reproductive hazard. <u>Microcrystalline Cellulose</u> Assessment Reproductive Toxicity Data indicate that this compound is not a reproductive hazard. 		

Animahan
 Apixaban 10 Days oral (daily) exposure time = 10 Days Study of Embryo-Fetal Development (mouse) (parent, females) LOAEL = 600 mg/kg Maternal effects include: changes in blood clotting parameters. No effects were observed in the fetus/embryo. 9 Days oral (daily) Study of Embryo-Fetal Development (rat) (parent, females) LOAEL = 100 mg/kg (embryo/fetus) NOAEL = 3000 mg/kg (mbryo/fetus) NOAEL = 3000 mg/kg (mbryo/fetus) NOAEL = 3000 mg/kg (embryo/fetus) NOAEL = 1500 mg/kg (embryo/fetus) NOAEL = 125 mg/kg (embryo/fetus) NOAEL = 5 mg/kg Maternal effects include: damage at injection sites, changes in blood clotting parameters. No effects were observed in the fetus/embryo. oral Study of Pre- and Postnatal Development (rat) (parent, females) LOAEL = 25 mg/kg (F1 offspring) NOAEL = 25 mg/kg Offspring effects include: decreased fertility. Maternal effects include: changes in blood clotting parameters. Developmental Toxicity Assessment No adverse developmental effects were observed in animal studies. Anticoagulants may cause increased bleeding during childbirth. <u>Microerystalline Cellulose Developmental Toxicity Assessment Available data do not indicate a potential for selective developmental toxicity. <u>Sodium Lauryl Sulfate Developmental Toxic</u></u>
Experiences with Human Exposure Apixaban oral Clinical trial(s) low exposure - acute effects include: headache, dizziness, bleeding, bruising, blood in stool, bloody urine, nausea. low exposure - long term exposure effects include: constipation, fever, cerebral bleeding. <u>Titanium Dioxide</u> Incident report(s) worker exposure low exposure - acute effects include: cough, breathing difficulties, rhinitis, Irritating to respiratory system

11. TOXICOLOGICAL	INFORMATION
Target Organs	<u>Apixaban</u> blood
	<u>Magnesium Stearate</u> central nervous system, cardiovascular system
	<u>Hydroxypropyl Methylcellulose</u> Eyes
	<u>Titanium Dioxide</u> lungs
Symptoms	<u>Apixaban</u> See "Human Experience".
	Microcrystalline Cellulose labored respiration, noisy respiration, chest pain, breathing difficulties, shortness of breath, lung inflammation
	Sodium Lauryl Sulfate nausea, vomiting, diarrhoea, dryness and cracking of skin, rash, redness and swelling of skin and eyes, breathing difficulties, cough, chest pain, congestion, burning, laryngitis
	Magnesium Stearate redness and swelling of eyes, skin flushing, nausea, vomiting, diarrhoea, dehydration, lowered blood pressure, cardiac irregularities, CNS depression, respiratory disorder, paralysis
Pharmacokinetics/ Toxicokinetics	<u>Apixaban</u> Absorption: Not available Distribution: Not available Metabolism: Not available Elimination: Half-life = 12 Hour(s) (Human).
Other Toxicity Information	Other Toxicity TestsApixabanTelemetry Study (dog) : intravenous = 1.25 - 4 mg/kg No significant adverse effects were observed. No significant cardiovascular or hemodynamic effects noted. Phototoxicity : In vitro = negative

12. ECOLOGICAL INFORMATION	
Ecotoxicity effects	
Acute Toxicity to Fish	
Sodium Lauryl Sulfate	
	elas (fathead minnow), 96 H) : 10.2 mg/l.
	ykiss (rainbow trout), 96 H) : 4.6 mg/l.
Acute Toxicity to Aquatic In	
Sodium Lauryl Sulfate	
EC50 (Daphnia, 48 H)	· 1 8 mg/l
Toxicity to aquatic plants	
Apixaban	
	lla subcapitata (formerly Selenastrum capricornutum)) :> 23 mg/l
	ella subcapitata (formerly Selenastrum capricornutum)) : 3.6 mg/l
Sodium Lauryl Sulfate	
	ospicatus, 72 H) : 53 mg/l
Toxicity to microorganisms	oproacao, (211) : 55 mg 1
Apixaban	
Respiration inhibition, E0	$C50 \cdot > 1.000 \text{ mg/l}$
Sodium Lauryl Sulfate	250 . 7 1,000 mg/r
	bhosphoreum, 5 Minute) : 1.19 mg/l
Chronic toxicity to fish	hosphoreum, e himde) : 1:19 mg f
<u>Apixaban</u>	
	Pimephales promelas (fathead minnow)) : > 10 mg/l NOEC : 10 mg/l
Chronic toxicity to aquatic i	
<u>Apixaban</u>	invertablates
LOEC (Daphnia magna (Water flea)) : 23 mg/l
NOEC (Daphnia magna (
NOLC (Dupining haging ((water field)). 9.0 fills/f
Mobility	Not available
Persistence and degradability	
Biodegradation	
<u>Apixaban</u>	
Ready biodegradation : 0	% ; Not readily biodegradable.
<u>Apixaban</u>	
Koc (soil) : 12.2	
PBT and vPvB Assessment:	Not available
13. DISPOSAL CONSIDERATIONS	
Advice On Disposal And Packaging	Disposal should be in accordance with applicable regional, national and local
1	laws and regulations. Local regulations may be more stringent than regional
	or national requirements. This information presented only applies to the
	material as supplied.
Other information	
	This information presented only applies to the material as supplied.

14. TRANSPORT INFORMATION

This material is not a dangerous good for the purpose of transportation.

15. REGULATORY INFORMATION

United States of America

15. REGULATORY INFORMATION					
313 Toxic Release Inventory	No components listed on the SARA 313 inventory.				
TSCA Inventory	Not listed. Food, drug and cosmetic products are exempt from TSCA.				
EU Directive 1999/4	5/EC				
BULK MATERI	AL				
Symbol(s)	Xn: Harmful Xi: Irritant				
R-phrase(s)	 R37: Irritating to respiratory system. R40: Limited evidence of a carcinogenic effect. inhalation R48/22: Harmful: danger of serious damage to health by prolonged exposure if swallowed. 				
S-phrase(s)	 S22: Do not breathe dust. S36/37/39: Wear suitable protective clothing, gloves and eye/face protection. S38: In case of insufficient ventilation, wear suitable respiratory equipment. S45: In case of accident or if you feel unwell, seek medical advice immediately (show label where possible). S53: Avoid exposure - obtain special instructions before use. S60: This material and its container must be disposed of as hazardous waste. 				
DRUG PRODUC	<u>CT</u>				
Classification	Medicinal products are exempt from classification and labeling requirements under EU Preparations Directive 1999/45/EC.				
Regulatory Authorizations and Restrictions:	Not available				

16. OTHER INFORMATION						
Text of Symbol(s), R-phrase(s) and H-code(s) mentioned in Section 3						
H302 Harmful if swallowed.						
H311	Toxic in contact with skin.					
H315	Causes skin irritation.					
H318	Causes severe eye damage.					
Н335	May cause respiratory irritation					
H351	Suspected of causing cancer.					
Н372	Causes damage to organs through prolonged or repeated exposure.					
H413	May cause long lasting harmful effects to aquatic life.					
Ν	Dangerous for the environment					
R21	Harmful in contact with skin.					
R22	Harmful if swallowed.					
R36/37/38	Irritating to eyes, respiratory system and skin.					
R37	Irritating to respiratory system.					
R40	Limited evidence of a carcinogenic effect.					
R48/25	Toxic: danger of serious damage to health by prolonged exposure if swallowed.					
R51/53	Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.					

	R53 T Xi Xn	May cause long-term adverse Toxic Irritant Harmful	e effects in the aquatic environment.			
Recommended Restrictions for						
	Not availab	le				
SDS preparation information						
Prepared by	Research and Development Environment, Health and Safety 1-732-227-7380					
Prepared on						
		Data Sheet has been revised. ersion in section(s): 1, and 16.	This data sheet contains changes from the			
Other information	•					
HMIS	Health		2*			
	Flammability		Not Determined (ND)			
	Reactivity		Not Determined (ND)			
	Perso	nal protective equipment	See Section 8.			
NFPA	Health Fire Reactivity Special	2 ND ND ND	2 ND ND			

Country- Specific Emergency Phone Numbers	CHEMTREC In-Country Dial Numbers	Local # Provided in Country	Toll Free in Country*	Greeting Language	
	CHEMTREC South Africa*	Comparison of Co	0-800-983-611	English	
			0-800-983-011		
	CHEMTREC Argentina (Buenos Aires)	+(54)-1159839431		Latin American Spanish	
	CHEMTREC Brazil (Rio De Janeiro)	+(55)-2139581449		Portuguese	
	CHEMTREC Chile (Santiago)	+(56)-25814934		Latin American Spanish	
	CHEMTREC Colombia *		01800-710-2151	Latin American Spanish	
	CHEMTREC Mexico*		01-800-681-9531	Latin American Spanish	
	CHEMTREC Peru (Lima)	+(51)-17071295		Latin American Spanish	
	CHEMTREC China*	4001-204937		Mandarin	
	CHEMTREC Hong Kong (Hong Kong)*		800-968-793	Cantonese	
	CHEMTREC India *		000-800-100-7141	Hindi	
	CHEMTREC Indonesia*		001-803-017-9114	Indonesian	
	CHEMTREC Japan (Tokyo)	+(81)-345209637		Japanese	
	CHEMTREC Malaysia *		1-800-815-308	Malay	
	CHEMTREC Philippines *	9	1-800-1-116-1020	Tagalog	
	CHEMTREC Singapore*		800-101-2201	Mandarin	
	CHEMTREC Singapore	+(65)-31581349		Mandarin	
	CHEMTREC South Korea*		00-308-13-2549	Korean	
	CHEMTREC Taiwan*		00801-14-8954	Mandarin	
	CHEMTREC Thailand *		001-800-13-203- 9987	Thai	
	CHEMTREC Vietnam (Ho Chi Minh City)	+(84}-838012436		Vietnamese	
	CHEMTREC Australia (Sydney)	+(61)-290372994		English	
	CHEMTREC Belgium (Brussels)	+(32)-28083237		French and Flemish	
	CHEMTREC Czech Republic (Prague)	+(420)-228880039		Czech	
	CHEMTREC France	+(33)-975181407		French	
	CHEMTREC Germany *	1001-010202401	0800-181-7059	German	
	CHEMTREC Hungary (Budapest)	+(36)-18088425		Hungarian	
	CHEMTREC Italy *		800-789-767	Italian	
	CHEMTREC Italy (Milan)	+(39)-0245557031		Italian	
	CHEMTREC Netherlands	+(31)-858880596		Dutch	
	CHEMTREC Poland (Warsaw)	+(48)-223988029		Polish	
	CHEMTREC Spain*		900-868538	European Spanish	
	CHEMTREC Sweden (Stockholm)	+(46)-852503403		Swedish	
	CHEMTREC Switzerland (Zurich)	+(41)-435016715		German	
	CHEMTREC UK (London)	+(44)-870-8200418		English	
	CHEMTREC Bahrain (Bahrain)	+(973)-16199372		Arabic	
	CHEMTREC Israel (Tel Aviv)	+(972)-37630639		Hebrew	
	*Phone numbers for countries marked with an asterisk must be dialed within the country				
The information contained in th	his SDS is believed to be accurate and represents the best information reasonably				
		ranty, express or imp			

information. and we assume no liability from its use.